Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants priority review to sBLA for daratumumab in multiple myeloma

Oct. 10, 2016

EnGeneIc and Teva collaborate on EDV-based immunomodulatory therapies for cancer

Oct. 10, 2016

Teva to commercialize two Celltrion biosimilar candidates in U.S. and Canada

Oct. 7, 2016

Vaccinex, Merck KGaA form collaboration to evaluate VX15/2503 plus avelumab in NSCLC

Oct. 7, 2016

Triphase Accelerator obtains rights to ADC from Catalent Biologics

Oct. 6, 2016

Achilles Therapeutics launched to develop immunotherapies for cancer

Oct. 6, 2016

Altor and NantKwest sign cancer immunotherapy codevelopment agreement

Oct. 5, 2016

Daiichi Sankyo enters collaboration with AgonOx to develop immuno-oncology target

Oct. 5, 2016

Morphotek signs exclusive license agreement with Eurofarma Laboratiorios

Oct. 5, 2016

EMA accepts for review MAA for Herceptin biosimilar SB-3

Oct. 4, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...